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a  b  s  t  r  a  c  t
Background:  Segmental  tissue  loss  in  the  lateral  meniscus  is  associated  with  pain  and  increased  risk  of
osteoarthritis  even  when  indications  have  been  carefully  considered.
Hypothesis:  Repairing  the defect  using  a novel  biodegradable  scaffold  will reduce  pain  and  restore  the
knee  function.
Methods:  In this  prospective  multicenter  study,  a  total  of  54  patients  (37 males/17  females;  mean  age:
28  years  [16–50])  were  enrolled.  All  patients  presented  with  postmeniscectomy  syndrome  and  seg-
mental  lateral  meniscus  loss,  and  were  treated  with  a polyurethane  biodegradable  scaffold  (Actiﬁt®,
Orteq)  implanted  arthroscopically.  Clinical  outcomes  were  assessed  at 6, 12 and  24  months  using  Visual
Analogue  Scale  (VAS),  International  Knee  Documentation  Committee  Score  (IKDC)  and  Knee  Injury and
Osteoarthritis  Outcome  Score  (KOOS).
Results:  VAS  decreased  from  5.5  at baseline  to 3.6  at 6 months,  3.4  at 12  months  and  2.9 at  24 months.
IKDC  improved  from  47.0  at baseline  to 60.2,  67.0  and  67.0  at 6, 12  and  24  months.  All  KOOS  subscores
improved  between  baseline  and  24  months.
Discussion:  Clinical  results  of  this  study  demonstrate  clinically  and  statistically  signiﬁcant  improvements
of  pain  and  function  scores  (VAS,  IKDC,  and  all KOOS  subscales  except  sport),  at  the  6 months  follow-up
and  on all  clinical  outcomes  at  the 2-year  follow-up.  The  Actiﬁt® scaffold  is  safe  and  effective  in  treating
lateral  meniscus  defects.
Level  of evidence:  IV: continuous  prospective  multicenter  study.. Introduction
The menisci play an important biomechanical role in the knee
ncluding load bearing, load and force distribution between the
emoral condyles and tibial plateau, joint stabilization, lubrica-
ion and proprioception [1]. This is especially important in the
ateral compartment which is considered to be more biomechani-
ally challenging, as the lateral meniscus has a smaller contact area
ombined with higher peak stresses when compared to the medial
eniscus under various loads, degrees of ﬂexion and meniscectomy
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conditions. Furthermore, the lateral compartment is more mobile
than the medial as the antero-posterior translation is greater [2,3].
The standard of care for irreparable meniscal tears, partial lateral
meniscectomy, is well known to predispose patients to long-term
degenerative changes and osteoarthritis [4,5]. Furthermore, worse
outcomes have been reported following lateral rather than medial
meniscectomy [6,7]. In a 30-year longitudinal study, McNicholas
et al. [8] found that after medial meniscectomy 80% of patients
had good or excellent results at long-term follow-up, compared
to only 47% after lateral meniscectomy, thus there are even greater
negative consequences following meniscal tissue loss in the lateral
compartment. Chatain [6] when comparing results of 109 lateral
and 362 medial partial meniscectomies with more than 10 years






























Following the implantation of Actiﬁt® scaffold, rehabilitation54 H. Bouyarmane et al. / Orthopaedics & Traum
imilar but radiographic results, in particular, joint space narrowing
re signiﬁcantly worse in the lateral compartment.
The unacceptably low rate of success following lateral partial
eniscectomy, common to all current standard procedures, has led
o a genuine need for an approach which will offer patients bet-
er and more reliable treatment. Meniscal reconstruction would
e the solution to this problem; by allograft in the case of total
eniscectomy or scaffold in the case of a partial defect with the
im of closely mimicking the shape and biomechanical proper-
ies of the native meniscus [9,10]. The novel porous biodegradable
olyurethane scaffold (Actiﬁt®) is intended to meet this unmet
eed, by providing a scaffold for vessel ingrowth and meniscal tis-
ue regeneration. Studies have shown that treatment of irreparable
eniscal tissue loss with the polyurethane scaffold is both safe
nd efﬁcacious in mixed populations of medial and lateral patients
11,12]. However, no data are currently available that focus on the
ore biomechanically challenging lateral indication.
The objective of this study was to clinically evaluate the lat-
ral polyurethane scaffold for the treatment of patients with
ateral segmental tissue loss with postmeniscectomy syndrome.
e hypothesize that the lateral polyurethane meniscal scaffold,
ndicated in case of partial defect, is able to reduce pain and restore
nee function.
. Materials and methodsThis study was a prospective, single-arm, multicentre study
esigned to assess the safety and efﬁcacy of the lateral
olyurethane meniscal scaffold (Actiﬁt®, Orteq Ltd, London, UK) for
he treatment of postmeniscectomy syndrome (Fig. 1a). A total of
ig. 1. a: the polyurethane scaffold is available in both medial (A) and lateral (B)
onﬁgurations; b: measurement of defect length.gy: Surgery & Research 100 (2014) 153–157
54 patients from six European centres were enrolled between 2007
and 2011 who  were treated with the polyurethane scaffold for post-
meniscectomy syndrome. Inclusion criteria were the same as used
by Verdonk et al. [11], but in brief comprised; (1) irreparable painful
lateral meniscal tear or partial meniscus loss, with intact rim; (2)
skeletally mature male or female patients; (3) age 16 to 50 years;
(4) stable knee joint or knee joint stabilization procedure within
12 weeks of index procedure; (5) International Cartilage Repair
Society (ICRS) classiﬁcation ≤ 3 and (6) body mass index ≤ 35.
2.1. Surgical technique
Following exploration of all compartments and veriﬁcation of
cartilage status, debridement and preparation were performed: the
defects extended into the vascularized red-on-red or red-on-white
zone of the damaged portion of the meniscus. The meniscal defect
was measured along the curvature of its inner edge using a special
meniscal ruler (Fig. 1b), then the scaffold was cut to size; with the
scaffold oversized by 10% to allow for shortening caused by sutur-
ing. The implant was  introduced into the joint by the anterolateral
portal and then ﬁxed to the native meniscus by sutures (using all
inside devices, and/or outside-in techniques) (Fig. 2).was provided as per the procedure described by Verdonk et al. [13].
Fig. 2. a: suture of scaffold to native meniscus; b: 24-month relook showing tissue
ingrowth into the scaffold at the interface with the native meniscus.
Courtesy S. Roberts.



















































Fig. 3. VAS improvement from baseline (last observation carried forward) to
24 months.
Fig. 4. IDKC improvement from baseline (last observation carried forward) to
24 months.
Fig. 5. KOOS subscales improvement from baseline (last observation carried for-H. Bouyarmane et al. / Orthopaedics & Traum
ehabilitation took place over 16–24 weeks, with the patient non-
eight-bearing for the ﬁrst 3 weeks, partial weight-bearing from
eek 4 with gradual increase in loading up to 100% load at 9 weeks
ost-implantation. Flexion was progressively increased from 30◦
uring 2 weeks to 60◦ in week 3 and 90◦ in weeks 4 and 5. From
eek 6 onwards, ﬂexion is further increased until a full range of
otion is achieved. Light exercise, including isometric quadriceps
xercises, mobilisation of the patella, heel slides, quad sets, anti-
quinus foot exercises and Achilles tendon stretching, is advised
rom week 1.
.3. Clinical outcomes
Patients were assessed at 6, 12 and 24 months postoperatively
ollow-up visits using the VAS, IKDC scores and KOOS clinical out-
ome scores.
.4. Statistical methods
All evaluations were based on all patients enrolled into the
tudy and implanted with the scaffold. The last observation carried
orward (LOCF) [14,15] approach was used; that is data from the
ast available follow-up visit were used in place of missing scores
ue to patient withdrawal, loss to follow-up, or non-evaluable
AS or other outcome questionnaire data. Total clinical outcome
cores were calculated according to standard formulae. Absolute
nd change from pre-surgery values were analyzed descriptively
including mean and 95 CI). And paired t-tests to test the null
ypothesis of mean change in outcome scores equal to zero were
arried out for each outcome score at each follow-up assessment
a 2-sided P < 0.05 was considered statistically signiﬁcant).
. Results
There were 37 men  and 17 women (mean age: 28 years,
ange16–50 years) enrolled in the study. All patients presented
ith postmeniscectomy syndrome following 1–3 prior meniscal
urgeries. There were 9 patients who had undergone anterior cru-
iate ligament reconstruction and 5 patients who had undergone
istal femoral varus osteotomies prior to taking part in this study.
The mean size of defect was 43 mm (32–60 mm).  The lateral
efects were primarily localized in both posterior and middle seg-
ents of the meniscus in 45% of cases, posterior in 27%, midpart
n 23% and across the segments for 5% of cases. At the time of
ctiﬁt® implantation, four patients received distal femoral varus
steotomy, one underwent chondral-shaving, one had a mobile
oose body removed and one underwent a microfracture procedure.
.1. Clinical outcome scores
There were no intra- or immediate postoperative complica-
ions. By 6 months, all clinical outcome scores showed clinically
igniﬁcant improvements from baseline, a trend which continued
n to 12 months. Between 12 and 24 months, VAS continued to
mprove (Fig. 3), IKDC and KOOS Quality of Life showed no signif-
cant regression, and the pain, symptoms, activities of daily living
nd sports domains of KOOS continued to improve (Figs. 4 and 5).
verall there were clinically and statistically signiﬁcant improve-
ents from baseline to 24 months for all clinical outcome scores
Table 1).
.2. ReoperationsDuring the course of 24 months follow-up period, a total of 3/54
5.5%) patients underwent exploratory arthroscopy due to pain.
ne of these patients, prior to receiving the scaffold, had medialward) to 24 months.
femoral condyle osteochodritis dissecans and had undergone ACL
reconstruction. After 7 months, a part of scaffold was removed,
outcomes were good at 3 years follow-up. The second patient, re-
operated 15 months post-implantation for pain, had small tear
localised in free edge of the scaffold which was trimmed to pre-
vent propogation. However, even though the scaffold was  well
integrated, pain continued. In the third case, the patient was  re-
operated on for new pain at 24 months postoperatively. A torn part
of the scaffold was  removed.
Results of these re-operated patients are included in the statis-
tics of our study.
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Table  1
Clinical outcome scores, VAS, IKDC and KOOS from baseline to 24 months.
Score Baseline 6 months 12 months 24 months (LOCF) n
VAS 5.51 ± 2.32 3.58 ± 2.63* 3.4 ± 2.70* 2.94 ± 2.52* 45
IKDC  46.96 ± 15.67 60.19 ± 20.20** 67.04 ± 20.24* 66.97 ± 18.34* 42
KOOS Symptoms 59.16 ± 19.42 73.84 ± 14.90* 77.33 ± 16.28 79.01 ± 16.11 30
KOOS  Pain 56.57 ± 17.61 69.15 ± 18.72*** 75.03 ± 18.45* 78.53 ± 17.24* 30
KOOS  ADL 64.06 ± 23.05 79.02 ± 16.33** 82.96 ± 16.96* 84.21 ± 15.26* 30
KOOS  Sport 30.05 ± 26.87 41.16 ± 27.42 (NS) 48.10 ± 28.82**** 54.03 ± 27.25*** 27
KOOS QOL 29.59 ± 16.94 44.42 ± 22.21** 52.18 ± 21.38* 50.93 ± 21.38* 30
Mean ± standard deviation. NS: not signiﬁcant.















































y** P < 0.0005.
*** P < 0.005.
**** P < 0.05.
. Discussion
The ﬁrst generation of meniscal scaffolds (collagen meniscal
mplant [CMI]) used to treat meniscal defects have been shown
o provide signiﬁcant improvements in function using the Lysholm
nd Tegner index [16–18]. Zaffagnini et al. [10] in a 10-year mini-
um follow-up study found statistically signiﬁcant improvements
n both clinical and radiological outcomes in the CMI group when
ompared with partial meniscectomy. Clinical evaluation using
ain, Lysholm scores and the Tegner index demonstrated signif-
cant improvements at 5-year follow-up which was  maintained
p to the 10 years follow-up. The CMI  is made from type 1 col-
agen derived from bovine achilles tendon, and has been reported
o present difﬁculty in handling and suturing during surgery, high-
ighting the need for newer scaffolds with improved material and
andling characteristics.
The second generation porous polyurethane scaffold is robust
nd ﬂexible when handling and has been reported to degrade into
on-toxic decomposition products [19,20], as well as supporting
igration of cells and ingrowth of new tissue in vitro and in vivo
11,21]. Preservation of cartilage status following implantation of
he polyurethane scaffold has also been demonstrated in several
tudies [13,22]. In addition, the frictional properties of the porous
olyurethane scaffold have been shown to approach those of native
eniscus after 6 to 12 months in sheep [23].
This is the ﬁrst study to focus solely on the use of the
olyurethane meniscal scaffold in the more challenging lateral indi-
ation. The main ﬁnding from this study is that lateral Actiﬁt®
eniscal scaffold is both safe and effective when used to treat
atients presenting with postmeniscectomy syndrome. Clinical
esults presented here demonstrate clinically and statistically sig-
iﬁcant improvements of pain and function scores (VAS, IKDC, and
ll KOOS subscales except sport) already at the 6 months follow-
p and on all clinical outcome scores between baseline and the
-year follow-up. With the exception of the VAS pain scores which
ontinue a trend of improvement between baseline through to
 years, the majority of improvement of the other clinical out-
ome scores were achieved during the ﬁrst year. Progression of
hese scores between 12 and 24 months is not signiﬁcant. Our
esults are in agreement with those published by Verdonk et al.
12] who reported comparable clinically and statistically signiﬁ-
ant improvements of all clinical outcome scores, in a 52-patient
tudy (34 medial and 18 lateral). Efe et al. [22] in a study con-
isting of 10 patients with pain as a result of segmental medial
eniscus loss, treated with Actiﬁt®, also found clinically and sta-
istically signiﬁcant improvement of KOOS scores from baseline to
2 months. The improvement in VAS pain scale reported by Efe
id not reach statistical signiﬁcance however, but patients were
eported as being satisﬁed with the results of their surgery and
hen asked if they would have the procedure repeated, all said
es.Radial displacement of polyurethane scaffold has been stud-
ied by De Coninck et al. [24]. The radial displacement of lateral
scaffold was not signiﬁcant between implantation and 24 months
follow-up relative to preoperative status, however this displace-
ment increased signiﬁcantly for medial scaffold.
The reoperation rate of 5.5% (3/54) reported here using the
polyurethane scaffold compares favourably with other forms of
meniscal surgery such as repair surgery previously reported: bio-
absorbable meniscal screws and arrows (33–68% reoperations
reported [25–28]) and all inside suture techniques (13–29% reop-
erations reported [29–32]). However, it must be noted that a direct
comparison with such techniques is not possible, as they would
not be indicated for the more challenging population of patients
reported in this study that had irreparable defects with limited
treatment options.
4.1. Limitations
A limitation of this single-arm study is the lack of a control
group of patients undergoing partial meniscectomy allowing a
direct comparison of the two treatment options. There are currently
no randomised control studies which assess the Actiﬁt® scaf-
fold; however, previous meniscal scaffold (CMI MenaﬂexTM Regen
Biologics) studies [10,16,17] have demonstrated beneﬁts with scaf-
folds both in terms of clinical results and cartilage preservation,
when compared with partial meniscectomy. Another limitation of
the multicentre approach utilised in this study was that poten-
tial bias and variation that could have been introduced from data
capture at each centre. The data was  reviewed and collated by an
independent assessor in order to mitigate any potential bias.
5. Conclusion
The frequency of sequelae following lateral meniscectomy
demonstrates the need for an effective treatment option. This
clinical study demonstrates both the safety and efﬁcacy of the
polyurethane scaffold used to treat partial defects of the lateral
meniscus at 24 months following implantation, thus providing sur-
geons with such a treatment option in this challenging patient
population. Further long-term research is required to further sup-
port the ﬁndings from this mid-term study.
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